European Psychiatry

Zopiclone: from clinical practice to quality of life. Introduction
pp. 81s-81s(1)
Author: Partinen M.

Quality of life measurement in the medical setting
pp. 83s-85s(3)
Author: Bech P.

Quality of life and insomnia validation study for a specifically designed questionnaire
pp. 87s-89s(3)
Authors: Jambon B.; Le Gal M.; Pilate C.

Effects of zopiclone on quality of life in insomnia
pp. 91s-94s(4)
Author: Hindmarch I.

Measuring the unmeasurable: the role and importance of quality of life measurement in economic evaluations of sleep disorder treatment
pp. 95s-98s(4)
Author: von der Schulenburg J.G.

Sleep, morning alertness and quality of life in subjects treated with zopiclone and in good sleepers. Study comparing 167 patients and 381 good sleepers
pp. 99s-102s(4)
Authors: Leger D.; Janus C.; Pellois A.; Quera-Salva M.; Dreyfus J.

The perspective of management of sleep disorders in Japan
pp. 103s-108s(6)
Author: Okuma T.

An overview of the report of the national commission on sleep disorders research
pp. 109s-113s(5)
Author: Roth T.

Health status or quality of life: which is relevant? Concluding remarks
pp. 115s-115s(1)
Author: Joyce C.

The mechanism of action of zopiclone
pp. 117s-128s(12)
Authors: Doble A.; Canton T.; Malgouris C.; Stutzmann J.; Piot O.; Bardone M.; Pauchet C.; Blanchard J.

Comparative study of the effects of zopiclone (7.5 mg), zolpidem, flunitrazepam and a placebo on nocturnal cognitive performance in healthy subjects, in relation to pharmacokinetics
pp. 129s-135s(7)
Authors: Allain H.; Patat A.; Lieury A.; Le Coz F.; Janus C.; Menard G.; Gandon J.

Zopiclone's residual effects on psychomotor and information processing skills involved in complex tasks such as car driving: a critical review
pp. 137s-143s(7)
Author: O'Hanlon J.

Withdrawal from benzodiazepines by initially switching to zopiclone
pp. 145s-151s(7)
Authors: Shapiro C.; Sherman D.; Peck D.

Differential illness intrusiveness associated with sleep-promoting medications
pp. 153s-159s(7)
Authors: Devins G.; Flanigan M.; Fleming J.; Morehouse R.; Moscovitch A.; Plamondon J.; Reinish L.; Shapiro C.

Gradual withdrawal of zopiclone (7.5 mg) and zolpidem (10 mg) in insomniacs treated for at least 3 months
pp. 161s-165s(5)
Authors: Lemoine P.; Allain H.; Janus C.; Sutet P.

Zopiclone in the treatment of insomnia in depressed patients
pp. 167s-172s(6)
Authors: Van Moffaert M.; Pilate C.

Effects of hypnotics on sleep quality and daytime well-being. Data from a comparative multicentre study in outpatients with insomnia
pp. 173s-179s(7)
Authors: Hajak G.; Clarenbach P.; Fischer W.; Haase W.; Bandelow B.; Adler L.; Ruther E.